Company Overview

Immutep Limited is an Australian biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company’s core scientific platform centers on lymphocyte activation gene-3 (LAG-3), an immune checkpoint molecule involved in regulating T-cell responses. Immutep operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on oncology therapeutics and immuno-oncology combinations. The company is publicly traded on the Australian Securities Exchange and also trades in the U.S. over-the-counter market under the ticker PRRUF.

The company’s principal product candidate is eftilagimod alpha (commonly referred to as “efti”), a soluble LAG-3 protein designed to stimulate antigen-presenting cells and enhance immune responses when combined with other cancer therapies, particularly PD-1 checkpoint inhibitors and chemotherapy. Immutep’s pipeline also includes additional LAG-3-related therapeutic assets for oncology and autoimmune indications. The company has positioned itself as a specialist in the LAG-3 field through proprietary intellectual property, clinical-stage development expertise, and collaborations with major pharmaceutical companies. Originally founded as Prima BioMed Ltd, the company later rebranded to Immutep to reflect its strategic concentration on LAG-3 immunotherapy research and development.

Business Operations

Immutep generates value primarily through clinical development programs, strategic licensing arrangements, collaboration agreements, and potential future commercialization opportunities tied to its immunotherapy pipeline. Its core operations are centered on the development of eftilagimod alpha and additional LAG-3 assets, including IMP761 and IMP731, which target autoimmune and immune-regulation pathways. The company conducts clinical trials across multiple countries and works with contract research organizations, academic institutions, and pharmaceutical partners to advance its development programs.

The company’s operational footprint includes activities in Australia, Europe, and the United States, with significant clinical and corporate functions based in Australia and France. Immutep controls a portfolio of patents and intellectual property related to LAG-3 biology and therapeutic applications. Strategic partnerships have included collaborations with companies such as Merck & Co. for studies involving KEYTRUDA (pembrolizumab) and relationships involving combination immunotherapy trials. The company also maintains subsidiaries and operational entities in Europe to support research, clinical management, and intellectual property administration.

Strategic Position & Investments

Immutep’s strategic direction is centered on expanding the clinical utility of LAG-3-based immunotherapies through combination treatment strategies in oncology. A major focus has been advancing late-stage clinical evaluation of eftilagimod alpha in metastatic breast cancer, non-small cell lung cancer, and head and neck cancers. The company has invested substantially in clinical trials evaluating efti alongside checkpoint inhibitors and standard-of-care therapies, aiming to demonstrate improved immune activation and patient outcomes.

The company has also pursued growth through licensing, research collaborations, and expansion of its immunotherapy platform beyond oncology into autoimmune disease applications. Immutep’s portfolio includes next-generation LAG-3 agonist and antagonist programs intended to address broader immune-modulation opportunities. Its strategic positioning is reinforced by specialization in a comparatively niche checkpoint target where it has accumulated significant intellectual property and clinical expertise. While the company remains pre-commercial, its development strategy emphasizes partnership-driven advancement and data generation from multinational clinical programs.

Geographic Footprint

Immutep is headquartered in Sydney, Australia, and maintains substantial operational and research activities in France through its European subsidiaries and scientific teams. The company’s clinical development activities extend across North America, Europe, and parts of the Asia-Pacific region through multinational oncology studies and collaboration networks.

Its market presence is primarily tied to global clinical research rather than commercial pharmaceutical sales, as the company remains in the clinical-stage biotechnology sector. Immutep’s international influence is driven by partnerships with global pharmaceutical companies, participation in international oncology conferences, and regulatory interactions across multiple jurisdictions including the United States, European Union, and Australia.

Leadership & Governance

Immutep’s leadership team combines biotechnology, pharmaceutical development, immunology, and capital markets experience. The company’s governance structure includes executives with backgrounds in oncology drug development and international clinical operations. Management has consistently emphasized advancing LAG-3 therapeutics through disciplined clinical execution, strategic collaborations, and scientific specialization.

Key executives include:

• Marc Voigt – Chief Executive Officer
• Frédéric Triebel, M.D., Ph.D. – Chief Scientific Officer
• Catherine Pickering – Chief Financial Officer
• Khadige Bouzelmat, Ph.D. – Senior Vice President, Clinical Development
• Christian Mueller – Chief Business Officer

The company was originally associated with biotechnology entrepreneur and investor activity tied to its predecessor entity, Prima BioMed Ltd, before evolving into a focused immunotherapy company under the Immutep name. Leadership communications and public filings have consistently highlighted the company’s strategy of leveraging LAG-3 expertise to build differentiated immunotherapy combinations for oncology and immune-related diseases.